An Add-on Study of MLR-1023 in Adults With Uncontrolled Type 2 Diabetes on Metformin Therapy

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 400 participants.

Also called NCT03279263

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 400 participants (planned count) (from the registry)
Sponsor
Melior Pharmaceuticals (from the registry)
Registry
  • NCT NCT03279263
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03279263. Randomized; triple masking; primary purpose treatment. Start 2017-09-01 (actual); primary completion 2019-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
An Add-on Study of MLR-1023 in Adults With Uncontrolled Type 2 Diabetes on Metformin Therapy
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
MLR-1023
Intervention (Other)
Placebo
Lead sponsor
Melior Pharmaceuticals (class: other)
Collaborator
Bukwang Pharmaceutical, Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct03279263
Content hash
cdf49624ce280ac9a457566e8d32329a14c950cbc00303a1479b68d84e02781e